Patients from 22+ countriesPlan your visit →
lutetium-therapy
Patient Journey · 10 Sept 2026

What to Expect 3-6 Months After Lu-177 PSMA Therapy

Finished your last cycle of lutetium Lu-177 vipivotide tetraxetan for mCRPC? This guide covers the blood tests, scans, PSA trends, and symptoms to expect in the 3 to 6 months after treatment ends.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 10 Sept 2026
What to Expect 3-6 Months After Lu-177 PSMA Therapy

What to Expect 3-6 Months After Lu-177 PSMA Therapy

This article is for men living with metastatic castration-resistant prostate cancer (mCRPC) who have finished a course of lutetium Lu-177 vipivotide tetraxetan (the radioligand therapy called Pluvicto). If you recently had your last cycle and are wondering what happens next, this article explains what your care team will monitor, what your results mean, and when to call the doctor.

After treatment ends, things change. You were going to appointments regularly. Now the schedule is lighter. But you still have questions. Is the therapy working? What do my blood results mean? When will my energy come back? These are normal things to wonder about.

What does follow-up look like after Lu-177 PSMA therapy?

  1. PSA blood test - usually every 8 to 12 weeks, to see if your PSA level is going up or down
  2. Full blood count - to check that your bone marrow has recovered and your blood cells are at safe levels
  3. Kidney function tests - measuring creatinine and eGFR (estimated glomerular filtration rate, which shows how well your kidneys are filtering) to make sure they are working OK
  4. CT scan of chest, abdomen, and pelvis - usually ordered around 3 months after your last cycle
  5. PSMA-PET scan - if PSA rises, your team may order this specialized scan to look for active cancer
  6. Symptom review - dry mouth, fatigue, bone pain, nausea, and any new concerns you want to raise

Your care team sets the exact schedule. The list above reflects standard practice used in major clinical trials of Lu-177 PSMA therapy, including protocols described in the clinical review of lutetium vipivotide tetraxetan on the NIH NCBI Bookshelf.

The first few weeks after your last cycle

Lutetium-177 has a physical half-life of about 6.7 days. This means the radioactive part breaks down quickly after each infusion. Within one to two weeks of your last cycle, most of the radiation has left your body. The National Cancer Institute notes that this short half-life is one reason lutetium therapy is practical to deliver and easier to manage than external radiation for most patients.

However, your body may still feel effects from the treatment for a few weeks. Common side effects are fatigue, dry mouth (called xerostomia), and nausea. According to FDA prescribing information for Pluvicto, in the VISION trial (the study that led to FDA approval), about 43% of patients reported fatigue and about 39% reported dry mouth.

Fatigue tends to peak during the last one or two cycles and then gets better. Many patients feel much better between week four and eight after the last infusion. Dry mouth can take longer to improve. Some patients see improvement after a few months. Others have some that doesn't go away. Staying well hydrated, using sugar-free gum, and asking your dentist about saliva substitutes can all help.

PSA at 3-6 months: what the numbers mean

PSA is a protein made by prostate cancer cells. After Lu-177 PSMA therapy, your team will check PSA regularly. But the numbers are not always straightforward.

Some patients see their PSA drop during or after treatment. A drop of 50% or more from your starting level is called a PSA response and usually means better long-term results. Others see PSA stay the same. A few see their PSA go up even when the cancer is responding (this is sometimes called a PSA flare). This doesn't mean the treatment failed. You can find a detailed explanation of these patterns in Reading PSA Trends During Lu-177 PSMA Therapy.

Your oncologist looks at the direction and speed of change, not a single number. A PSA that was falling during treatment but then stops is different from one that starts climbing. Ask your team what your trend means at each visit.

Try not to read too much into a single result. Your care team will look at the overall pattern over time, not one number in isolation.

Your first post-treatment scan

Most follow-up protocols include a CT scan of the chest, abdomen, and pelvis at roughly 3 months after the last cycle. This gives your oncologist a picture of what the cancer is doing in your major organs and lymph nodes.

If PSA is rising or you develop new symptoms, your team may also order a PSMA-PET scan. This specialized scan looks for PSMA (prostate-specific membrane antigen) on cancer cells. It can find active disease in bones, soft tissue, and organs that a CT scan might miss.

Results usually fall into a few types: shrinkage (when cancer has gotten smaller), stable disease (nothing has grown much), mixed response (some spots got smaller, others haven't), or progressive disease (cancer has grown or new spots have appeared). Each type leads to a different discussion about what to do next.

If you received treatment in another country (for example, in India) and are now back home, share your imaging with both your treating team and your home doctor. When both teams work together, you get the most complete picture of how you are responding.

What your blood tests are checking

Blood tests during follow-up serve two main purposes: checking for any late effects of treatment, and monitoring whether the cancer is affecting your blood-forming cells.

Full blood count (FBC or CBC): Lu-177 PSMA therapy targets cancer cells, but bone marrow (especially if you have bone metastases) can absorb some radiation too. Bone marrow makes all your blood cells. In some patients, blood counts drop during or after treatment. About 13% of patients in the VISION trial needed blood transfusions. Regular blood count and kidney checks are a normal part of follow-up care.

Kidney function: Lutetium passes through your kidneys. Creatinine and eGFR are checked at each visit. Most patients don't have kidney problems. Patients who had kidney issues before treatment are watched more closely.

Hemoglobin: Low hemoglobin often causes fatigue after treatment. If your levels are low, your doctor can discuss options to help.

Testosterone and hormone markers: If you are taking ADT (androgen deprivation therapy, which blocks hormones and is often continued alongside or after Lu-177 therapy), your team checks that your testosterone is suppressed. Most men with mCRPC keep taking ADT after finishing Lu-177 therapy.

Bone health during recovery

Many men with mCRPC have bone metastases. Long-term ADT also causes bone thinning over time (a condition called osteoporosis). Your team may check bone density with a DEXA scan, especially if you've been on hormone therapy for several years.

Eating more calcium, getting enough vitamin D, and doing weight-bearing exercise (if you're able) can help your bones during recovery. Some men take bone-protective medications like bisphosphonates or denosumab. Your doctor will advise if these are right for you.

Symptoms that may linger - and when they ease

Dry mouth: This side effect often lasts longer than others. Salivary glands have PSMA, so they absorb some radiation along with cancer cells. Brush your teeth regularly, see your dentist, and drink plenty of water - this helps most people. Mayo Clinic Press notes that dry mouth is expected because of how PSMA is present in salivary tissue.

Fatigue: Most people feel more energy in the first 2 to 3 months after your last cycle. If fatigue is bad or not getting better, tell your doctor. Other things (like anemia or pain) might be making it worse.

Bone pain: Some patients notice a temporary rise in bone pain in the days after an infusion (called a pain flare). By 3 to 6 months after your last cycle, this usually stops. If bone pain is getting worse at this point, tell your doctor. New or increasing bone pain after treatment may mean cancer is growing and needs imaging.

Nausea: This usually goes away first. Most people feel better within a few weeks of their last cycle.

If PSA rises or scans show progression

Not every patient has a lasting response to Lu-177 PSMA therapy. The VISION trial showed that this therapy improved survival more than standard care. The benefit was significant (hazard ratio 0.62, 95% confidence interval 0.52-0.74, p less than 0.001), according to the NCBI clinical review. This is good news for many patients, but individual responses vary.

If your PSA rises clearly after your last cycle, or imaging shows new or growing lesions, your doctor will want to talk about next steps. You may have other treatment options depending on your health, past treatments, and how the cancer is growing. See Lu-177 PSMA Resistance and Next Steps for mCRPC for more.

If you want to make sure all options are being considered, or if you had treatment in another country and are working with two teams, a second opinion from another cancer specialist can help. You can ask for a second opinion from Art of Healing Cancer about whether Lu-177 is the right next step or what other options exist.

Questions to ask at your 3-month visit

  • What does my PSA trend tell us - response, stable disease, or early progression?
  • What imaging do you recommend and when should I have it?
  • Are my blood counts and kidney function within a healthy range?
  • Should I continue or adjust my current hormone therapy?
  • What are the next treatment options if this course has not given enough benefit?
  • Is there a clinical trial that might suit me at this stage?

If you had Lu-177 PSMA treatment in another country and now see a different doctor at home, bring all your records: cycle dates, total radiation dose, SPECT/CT images after treatment, and blood tests from the treatment period. This helps your home team understand what happened and continue your care. See What to Expect in Your First Lu-177 PSMA Cycle for the full picture.

When to talk to your doctor

Contact your oncologist or care team between scheduled appointments if you notice any of the following:

  • Severe tiredness that is getting worse, not better
  • Fever above 38 degrees Celsius, chills, or other signs of infection
  • Decreased urine output or pain when urinating
  • New or worsening bone pain
  • Unexplained bruising or bleeding
  • New swelling in the legs or ankles

These symptoms don't always mean something serious is wrong. But they're worth a prompt call rather than waiting until your next scheduled visit.

If you want a review of your results (your PSA trend, imaging, or blood tests) or want to understand your options, you can contact the Lutetium Therapy team for a consultation. If Lu-177 is not the right next step for you, other options may be available.

This article is for general educational purposes and is not a substitute for personalised medical advice from a qualified oncologist.

Frequently asked questions

How long does fatigue last after Lu-177 PSMA therapy?

Fatigue is common during and after treatment. For most patients, it improves gradually in the weeks following the final cycle. Many notice a real difference by 4 to 8 weeks. If fatigue is severe or not improving after 2 to 3 months, mention it to your care team - low blood counts (anaemia) may be contributing and can often be addressed.

What PSA reading counts as a response to Lu-177 PSMA therapy?

A drop of 50% or more from your starting PSA level is generally called a PSA response in clinical studies and is associated with better outcomes. But PSA can temporarily rise before it falls - sometimes called a PSA flare - and that does not necessarily mean the therapy has failed. Your oncologist will look at the overall trend over several months rather than any single reading.

When will I have my first scan after completing Lu-177 PSMA treatment?

Most protocols include a CT scan of the chest, abdomen, and pelvis at around 3 months after the last cycle. If PSA is rising or you develop new symptoms, a PSMA-PET scan may be ordered sooner. Your care team will set the exact timing based on your individual situation and test results.

Can Lu-177 PSMA therapy cause kidney damage?

Lutetium is filtered through the kidneys, so kidney function is monitored with blood tests throughout and after treatment. Most patients do not develop significant kidney problems. Those who had reduced kidney function before starting treatment are watched more closely. If you notice changes in urine output or new swelling in your legs, tell your doctor promptly rather than waiting for your next scheduled appointment.

What happens if my PSA rises after the last Lu-177 PSMA cycle?

A rising PSA after completing treatment is a signal worth discussing with your oncologist. It may indicate disease progression. Your team will likely order imaging to see where the cancer is active and then discuss next treatment options. What is available depends on your prior treatment history, performance status, and how the cancer is behaving on imaging.

Is dry mouth permanent after Lu-177 PSMA treatment?

Dry mouth (xerostomia) is one of the more persistent side effects because the salivary glands express PSMA and absorb some radiation during therapy. For many patients it improves over several months. For others, a mild degree persists longer term. Good hydration, sugar-free gum, regular dental check-ups, and saliva substitutes can all help manage it day to day.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

After Lu-177 PSMA Therapy: 3-6 Month Follow-Up | lutetium-therapy